125526-06-9

Upstream product

• 125500-44-9 3-butyryl-4-chloro-8-(4-methoxybenzoyloxymethyl)-quinoline 
• 95-53-4 o-toluidine 
• 3249-68-1 ethyl butyroyl acetate 
• 125500-84-7 ethyl 2-(ethoxymethylene)-3-oxohexanoate 
• 125500-85-8 2-[1-(2-Hydroxymethyl-phenylamino)-meth-(Z)-ylidene]-3-oxo-hexanoic acid ethyl ester 
• 125500-43-8 3-butyryl-8-(4-methoxybenzoyloxy-methyl)-4(1H)-quinolone 
• 125500-42-7 4-Methoxy-benzoic acid 2-((Z)-2-ethoxycarbonyl-3-oxo-hex-1-enylamino)-benzyl ester 

Downstream Products

• 164861-10-3 1-[8-(1-Hydroxy-allyl)-4-o-tolylamino-quinolin-3-yl]-butan-1-one 
• 135385-24-9 1-(8-Oxiranyl-4-o-tolylamino-quinolin-3-yl)-butan-1-one 
• 125500-48-3 3-Butyryl-4-(2-methylphenylamino)quinoline-8-carbaldehyde 
• 125500-21-2 3-butyryl-4-(2-methylphenylamino)-8-(hydroxymethyl)quinoline 

Relevant academic research and scientific papers

Reversible inhibitors of the gastric (H+/K+)-ATPase. 4. Identification of an inhibitor with an intermediate duration of action

3-Acyl-4-(arylamino)quinolines were previously identified as gastric (H+/K+)-ATPase inhibitors, and clinical efficacy has been demonstrated for compound 3 (SK and F 96067). In the present study the further structure- activity relatio